COVID-19 and VTE: Prognostic Markers to Anticoagulation Protocols

COVID-19 Coagulopathy and Prognostic Biomarkers

Multiple cohort studies found rising D-dimer, IL-6, LDH, and high sensitivity troponin levels predicted mortality in hospitalized COVID-19 patients, with about 71 percent of nonsurvivors meeting DIC criteria, though bleeding remained uncommon despite the coagulopathy.

VTE Incidence Across Care Settings

Meta-analyses by Jimenez and Zhang and an adjudicated registry by Piazza found overall VTE incidence near 17 percent, rising to roughly 27 to 31 percent among ICU patients versus 4 to 7 percent on general wards, with major bleeding around 4 percent.

Post-Discharge VTE Risk

Outpatient studies by Salisbury and Patel following patients discharged without anticoagulation found symptomatic venous thromboembolism at 30 to 42 days occurred in only about 2 to 3 percent, informing more selective post-discharge prophylaxis.

A Risk-Stratified Anticoagulation Protocol

Merli’s institution dosed heparin or enoxaparin by renal function and patient weight for inpatients, then used validated VTE and bleeding risk scores to select outpatient enoxaparin or rivaroxaban, noting that ISTH, NIH, and Anticoagulation Forum guidance still differ on optimal intensity.